Work on bridging biomarker gaps for very low birth weight (VLBW) sepsis tests highlights ongoing unmet needs in neonatal diagnostics. Sepsis remains a leading cause of morbidity and mortality in this population, but clinicians lack sufficiently reliable tools to guide early diagnosis and treatment decisions. The article points to renewed attention on biomarker-based strategies and the need to evaluate performance across clinically relevant time windows and patient subgroups. For biotech, the framing underscores a development opportunity in diagnostic assays that can withstand real-world variability. Because VLBW infants are physiologically distinct from older children and adults, the report notes the importance of validating biomarkers specifically for neonatal sepsis rather than extrapolating from adult or pediatric data. The focus on “bridging” gaps suggests industry and research efforts are converging on improving assay sensitivity, specificity, and operational feasibility in NICU settings.